Possible mechanisms of cancer prevention by nicotinamide. (3rd June 2020)

• Record Type: Journal Article
• Authors: Buqué, Aitziber; Bloy, Norma; Kroemer, Guido; Galluzzi, Lorenzo
• Is Part Of: British journal of pharmacology. Volume 178:Number 10(2021)
• Page Start: 2034
• Page End: 2040
• Publication Date: 2020-06-03
• Subjects: Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.15096
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Nicotinamide (NAM) is a precursor of vitamin B3 commonly sold over the counter as a nutritional supplement with anti‐aging properties. Accumulating preclinical evidence indicates that NAM also mediates oncopreventive effects against a variety of neoplasms. Supporting the translational relevance of dietary NAM supplementation, results from a Phase 3 randomized clinical trial have demonstrated that oral NAM was safe and efficiently reduced the incidence of new non‐melanoma skin cancers and actinic keratosis amongst high‐risk individuals. However, the molecular and cellular mechanisms that underlie this ability of NAM to delay carcinogenesis remain to be clarified, as discussed in this short review. LINKED ARTICLES: This article is part of a themed issue on Cellular metabolism and diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.10/issuetoc